*9.1.2. Apricitabine*

Apricitabine (AVX754, formerly SPD754) is a drug for oral administration and is in the experimental phase (Phase IIB clinical trial). It is structurally related to lamivudine and emtricitabine and, as such, is an analog of cytidine [148]. This drug is well tolerated, and its most common side effects include headache, nausea, muscle aches and diarrhea. The use of apricitabine in HIV-1 patients had no effect on bone marrow, liver or kidney toxicity, and lipase. However, its use causes changes in lipid metabolism, most noticeable by elevated serum TG, indicating that its use should be evaluated in patients who initiated therapy with aprici‐ tabine or who already have a dyslipidemic profile [148-150].
